Skip to main content
Premium Trial:

Request an Annual Quote

Fingers Crossed, But We're Not Holding Our Breath

Derek Lowe has a post at In the Pipeline about Merck's new venture in open access. Sage, which will be headed up by Stephen Friend, is meant to "bring together genomic studies from all sorts of laboratories into a common format and database," Lowe writes. He says that challenges with IP and with varying data formats will be a major hurdle for the project -- and is none too sure the venture will "[get] off the ground at all. ... The analogy with open-source software doesn’t hold up so well with most scientific research these days, since the entry barriers (facilities, equipment, and money) are significantly higher than they are in coding."

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.